Discovery of new pyrimidopyrrolizine/indolizine-based derivatives as P-glycoprotein inhibitors : Design, synthesis, cytotoxicity, and MDR reversal activities
Copyright © 2021 Elsevier Masson SAS. All rights reserved..
Targeting P-glycoprotein (P-gp, ABCB1 transporter), which plays an essential role in multi-drug resistance (MDR) in cancers, with new cytotoxic agents is a promising strategy in cancer chemotherapy. In the current study, we report the synthesis of thirteen novel pyrimidopyrrolizine, pyrimidoindolizine, and diazepinopyrrolizine derivatives. The new compounds exhibited cytotoxic activities against MCF7, A2780 and HT29 cancer cell lines (IC50 = 0.02-19.58 μM) and MRC5 (IC50 = 0.17-20.57 μM). The six most active compounds (23b, 24a,b and, 31c-e) were evaluated for their MDR reversal activities in MCF7/ADR cells. Mechanistic study using real-time PCR revealed the ability of compound 31c to inhibit P-gp. In addition, compound 31c increased the accumulation of Rho123 inside MCF7/ADR cells in a dose-dependent manner compared to verapamil. Compound 31c arrested the cell cycle of MCF7 cells at the G1 phase. Compound 31c also caused a significant dose-dependent increase of early and late apoptotic events. Molecular docking analysis revealed a high binding affinity for compound 31c toward P-gp. Like zosuquidar, compound 31c displayed one hydrogen bond and several hydrophobic interactions with amino acids in P-gp. These results indicated that compound 31c represents a potential anticancer candidate with MDR reversal activity.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:218 |
---|---|
Enthalten in: |
European journal of medicinal chemistry - 218(2021) vom: 05. Juni, Seite 113403 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Shawky, Ahmed M [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 06.08.2021 Date Revised 06.08.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.ejmech.2021.113403 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM323787134 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM323787134 | ||
003 | DE-627 | ||
005 | 20231225184929.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ejmech.2021.113403 |2 doi | |
028 | 5 | 2 | |a pubmed24n1079.xml |
035 | |a (DE-627)NLM323787134 | ||
035 | |a (NLM)33823396 | ||
035 | |a (PII)S0223-5234(21)00252-X | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Shawky, Ahmed M |e verfasserin |4 aut | |
245 | 1 | 0 | |a Discovery of new pyrimidopyrrolizine/indolizine-based derivatives as P-glycoprotein inhibitors |b Design, synthesis, cytotoxicity, and MDR reversal activities |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 06.08.2021 | ||
500 | |a Date Revised 06.08.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2021 Elsevier Masson SAS. All rights reserved. | ||
520 | |a Targeting P-glycoprotein (P-gp, ABCB1 transporter), which plays an essential role in multi-drug resistance (MDR) in cancers, with new cytotoxic agents is a promising strategy in cancer chemotherapy. In the current study, we report the synthesis of thirteen novel pyrimidopyrrolizine, pyrimidoindolizine, and diazepinopyrrolizine derivatives. The new compounds exhibited cytotoxic activities against MCF7, A2780 and HT29 cancer cell lines (IC50 = 0.02-19.58 μM) and MRC5 (IC50 = 0.17-20.57 μM). The six most active compounds (23b, 24a,b and, 31c-e) were evaluated for their MDR reversal activities in MCF7/ADR cells. Mechanistic study using real-time PCR revealed the ability of compound 31c to inhibit P-gp. In addition, compound 31c increased the accumulation of Rho123 inside MCF7/ADR cells in a dose-dependent manner compared to verapamil. Compound 31c arrested the cell cycle of MCF7 cells at the G1 phase. Compound 31c also caused a significant dose-dependent increase of early and late apoptotic events. Molecular docking analysis revealed a high binding affinity for compound 31c toward P-gp. Like zosuquidar, compound 31c displayed one hydrogen bond and several hydrophobic interactions with amino acids in P-gp. These results indicated that compound 31c represents a potential anticancer candidate with MDR reversal activity | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Cytotoxicity | |
650 | 4 | |a MDR reversal Activity | |
650 | 4 | |a P-glycoprotein inhibition | |
650 | 4 | |a Pyrimido[4,5-b]indolizine | |
650 | 4 | |a Pyrimido[4,5-b]pyrrolizine | |
650 | 7 | |a ATP Binding Cassette Transporter, Subfamily B |2 NLM | |
650 | 7 | |a Antineoplastic Agents |2 NLM | |
650 | 7 | |a Pyrimidines |2 NLM | |
650 | 7 | |a Pyrroles |2 NLM | |
700 | 1 | |a Abdalla, Ashraf N |e verfasserin |4 aut | |
700 | 1 | |a Ibrahim, Nashwa A |e verfasserin |4 aut | |
700 | 1 | |a Abourehab, Mohammed A S |e verfasserin |4 aut | |
700 | 1 | |a Gouda, Ahmed M |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t European journal of medicinal chemistry |d 1994 |g 218(2021) vom: 05. Juni, Seite 113403 |w (DE-627)NLM106608835 |x 1768-3254 |7 nnns |
773 | 1 | 8 | |g volume:218 |g year:2021 |g day:05 |g month:06 |g pages:113403 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejmech.2021.113403 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 218 |j 2021 |b 05 |c 06 |h 113403 |